24 completed, 1 not yet recruiting, 1 terminated. 26 Phase 2, 5 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 24, Not yet recruiting 1, Terminated 1 |
| Phase 3 | 5 | Completed 4, Not yet recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Allergic Rhinoconjunctivitis: new trials by email Literature Review of Allergic Rhinoconjunctivitis trials Research Report on Allergic Rhinoconjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of BLU-808 in Allergic Rhinoconjunctivitis BLU-808, Placebo - Allergic Rhinoconjunctivitis | Phase 2 | Completed | Blueprint Medicines Corporation | 21 | 2025-04-14 | 2026-09-03 |
| Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract 3,000 MM09, 9,000 MM09, Placebo sublingual - Allergic Rhinitis, Allergic Asthma | Phase 2 / Phase 3 | Not yet recruiting | Inmunotek S.L. | 90 | 2023-11-01 | 2023-10-23 |
| Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction Dupixent®, Grazax®, Dupixent® Placebo - Allergic Rhinoconjunctivitis, Grass Pollen Allergy | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 199 | 2020-11-05 | 2026-04-27 |
| Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis Norketotifen, Placebo - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Completed | Emergo Therapeutics, Inc. | 36 | 2019-04-01 | 2020-08-21 |
| Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study Intra-lymphatic allergenic extract, Intra-lymphatic placebo - Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis | Phase 2 | Completed | Christopher Thompson, MD | 21 | 2018-09-28 | 2021-04-20 |
| Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy SUBLIVAC FIX Phleum Prat. - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Completed | HAL Allergy | 168 | 2015-09-01 | 2019-09-13 |
| A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber SQ tree SLIT-tablet, Placebo - Allergic Rhinoconjunctivitis | Phase 2 | Completed | ALK-Abelló A/S | 219 | 2015-06-01 | 2017-01-19 |
| An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy AVANZ Cupressus - Allergic Rhinoconjunctivitis | Phase 2 | Completed | ALK-Abelló A/S | 52 | 2014-04-01 | 2015-01-06 |
| Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials Placebo, Allergovit 6-grasses - Allergic Rhinoconjunctivitis, Healthy Volunteers | Phase 2 | Terminated | Allergopharma GmbH & Co. KG | 158 | 2014-01-01 | 2018-01-17 |
| Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts DLE, Second generation anti histamines + Nasal corticosteroids - Allergic Rhinoconjunctivitis | Phase 2 | Completed | National Polytechnic Institute, Mexico | 30 | 2013-08-01 | 2015-07-28 |
| SUBLIVAC FIX Phleum Pratense DT/DRF SUBLIVAC FIX phleum prat., Placebo - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Completed | HAL Allergy | 266 | 2012-09-01 | 2013-05-29 |
| SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding SUBLIVAC FIX Birch - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Completed | HAL Allergy | 270 | 2012-07-01 | 2013-05-29 |
| Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract Allergovac depot - Allergic Rhinoconjunctivitis | Phase 2 | Completed | Roxall Medicina España S.A | 150 | 2012-05-01 | 2017-05-01 |
| Vitamin D and Grass Pollen Specific Immunotherapy Cholecalciferol, middle-chain fatty acids (carrier) - Allergic Rhinoconjunctivitis | Phase 2 | Completed | Charite University, Berlin, Germany | 35 | 2011-10-01 | 2015-06-25 |
| Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense Allergovac Depot, Placebo - Allergic Rhinoconjunctivitis | Phase 2 | Completed | Roxall Medicina España S.A | 151 | 2011-10-01 | 2019-04-29 |
| PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis Placebo, PURETHAL Mites 6,667 AU/ml, PURETHAL Mites 20,000 AU/ml - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Completed | HAL Allergy | 290 | 2011-09-01 | 2013-05-29 |
| Avanz Phleum Pratense Maintenance Dose Avanz Phleum pratense, Placebo - Allergic Rhinoconjunctivitis | Phase 2 / Phase 3 | Completed | ALK-Abelló A/S | 450 | 2011-09-01 | 2014-01-22 |
| An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy AVANZ Phleum pratense - Allergic Rhinoconjunctivitis | Phase 2 / Phase 3 | Completed | ALK-Abelló A/S | 199 | 2011-06-01 | 2015-03-06 |
| Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis Placebo, rBet v1-FV - Allergic Rhinoconjunctivitis | Phase 2 | Completed | Allergopharma GmbH & Co. KG | 37 | 2010-10-01 | 2014-01-24 |
| Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU) Bilastine - Allergic Rhinoconjunctivitis, Chronic Urticaria | Phase 1 / Phase 2 | Completed | Faes Farma, S.A. | 36 | 2010-01-01 | 2012-09-26 |
Showing 20 of 26. Sign in to see all of them.
Rhinitis, Allergic (8) · Hypersensitivity (6) · Rhinitis, Allergic, Seasonal (2) · Chronic Urticaria (1) · Conjunctivitis, Allergic (1) · Dust Mite Allergy (1) · Erythema (1) · Nasal Obstruction (1) · Pruritus (1) · Rhinitis (1) · Rhinitis, Allergic, Perennial (1) · Rhinorrhea (1) · Sneezing (1) · Urticaria (1)
Immune System Diseases (13) · Hypersensitivity, Immediate (9) · Nose Diseases (9) · Otorhinolaryngologic Diseases (9) · Respiratory Hypersensitivity (9) · Respiratory Tract Diseases (9) · Rhinitis (8) · Hypersensitivity (7) · Airway Obstruction (1) · Chronic Disease (1) · Conjunctival Diseases (1) · Conjunctivitis (1) · Disease Attributes (1) · Eye Diseases (1) · Infections (1)
Carrier State (1) · Cholecalciferol (1) · Grazax (1) · Immunotherapy (1) · Sublingual Immunotherapy (1) · Transdermal Patch (1) · Transfer Factor (1) · Vitamin D (1) · bilastine (1) · dupilumab (1) · grass pollen extract, alum-adsorbed (1) · norketotifen (1)
HAL Allergy (5) · ALK-Abelló A/S (4) · Allergopharma GmbH & Co. KG (3) · Artu Biologicals (2) · Roxall Medicina España S.A (2) · Blueprint Medicines Corporation (1) · Charite University, Berlin, Germany (1) · Christopher Thompson, MD (1) · Emergo Therapeutics, Inc. (1) · Faes Farma, S.A. (1) · Inmunotek S.L. (1) · Laboratorios Leti, S.L. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Polytechnic Institute, Mexico (1) · University of Zurich (1)
Germany (10) · Spain (5) · Canada (4) · Czechia (3) · Netherlands (3) · Bulgaria (2) · Hungary (2) · Lithuania (2) · Poland (2) · Slovakia (2) · Sweden (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1)
Peter Couroux, MD (2) · Albert Roger, MD (1) · Carmen Marcos, MD (1) · Carmen Panizo, MD (1) · Carmen Vidal, MD (1) · Celso Pereira, MD (1) · Christopher Thompson, MD (1) · Claus Bachert, PhD, MD (1) · Deepen Patel, MD, CCFP (1) · Dyonne van Duren, MD, PhD (1) · Emilio Alvarez Cuesta, MD (1)
PMID 23621350, PMID 26417901, PMID 32407947, PMID 33905129, PMID 37417619
2008 (1), 2009 (1), 2018 (1)